| Schedule of Net Loss Per Share |
|
|
|
Three Months Ended
September 30,
|
|
|
Nine Months Ended
September 30,
|
|
|
|
|
2015
|
|
|
2014
|
|
|
2015
|
|
|
2014
|
|
|
Net loss
|
|
|
$ |
(5,427,709 |
) |
|
$ |
(3,127,269 |
) |
|
$ |
(14,357,325 |
) |
|
$ |
(8,508,592 |
) |
|
Net loss: Non-controlling interest
|
|
|
|
(242,244 |
) |
|
|
(126,865 |
) |
|
|
(549,190 |
) |
|
|
(330,675 |
) |
|
Net loss attributable to Heat Biologics, Inc.
|
|
|
$ |
(5,185,465 |
) |
|
$ |
(3,000,404 |
) |
|
$ |
(13,808,135 |
) |
|
$ |
(8,177,917 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average number of common shares used in net loss per share attributable to Heat Biologics, Inc.—basic and diluted
|
|
|
|
8,408,376 |
|
|
|
6,469,272 |
|
|
|
7,880,637 |
|
|
|
6,445,129 |
|
|
Net loss per share attributable to Heat Biologics, Inc.—basic and diluted
|
|
|
$ |
(0.62 |
) |
|
$ |
(0.46 |
) |
|
$ |
(1.75 |
) |
|
$ |
(1.27 |
) |
|
|
|
For the years ended
December 31,
|
|
|
|
2014 |
|
|
2013 |
|
|
Net loss
|
|
$ |
(12,243,211 |
) |
|
$ |
(6,609,864 |
) |
|
Net loss: Non-controlling interest
|
|
|
(454,394 |
) |
|
|
(198,516 |
) |
|
Beneficial conversion charge
|
|
|
— |
|
|
|
(2,300,000 |
) |
|
Preferred Stock Dividend
|
|
|
— |
|
|
|
(361,668 |
) |
|
Net loss applicable to common stockholders
|
|
$ |
(11,788,817 |
) |
|
$ |
(9,073,016 |
) |
|
|
|
|
|
|
|
|
|
|
Weighted-average number of common shares used in net loss per share applicable to common stockholders—basic and diluted
|
|
|
6,454,866 |
|
|
|
3,747,357 |
|
|
Net loss per share applicable to common stockholders—basic and diluted
|
|
$ |
(1.83 |
) |
|
$ |
(2.42 |
) |
|
| Schedule of Potentially Dilutive Securities |
|
|
For the Nine Months Ended
September 30,
|
|
|
|
2015
|
|
2014
|
|
|
Outstanding stock options
|
|
|
1,106,895
|
|
|
836,961
|
|
|
Common stock warrants
|
|
|
17,392
|
|
|
17,392
|
|
|
Underwriters warrants
|
|
|
125,000
|
|
|
125,000
|
|
|
|
|
|
|
|
|
|
|
|
|
For the years ended
December 31,
|
|
|
|
2014 |
|
2013 |
|
|
Outstanding stock options
|
|
|
1,018,590
|
|
|
633,482
|
|
|
Common stock warrants
|
|
|
142,392
|
|
|
178,159
|
|
|